EUVIMEDEUVIMED entdecken
Crossref

Identification of a novel inhibitor of SARS‐CoV ‐2 main protease: an in silico , biochemical, and cell‐based approach

Aditya Trivedi iD, Vandana Kardam iD, Krishna Kishore Inampudi, Sudhanshu Vrati, Dharmender Gupta, Aekagra Singh iD, Sarala Rani Kayampeta, Mohan Babu Appaiahgari iD, Deepak Sehgal iD

The FEBS Journal · 2023

DOI: 10.1111/febs.16947 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FEBS Journal, 2023. Verfasst von Aditya Trivedi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, School of Natural Sciences, Shiv Nadar Institution of Eminence, Greater Noida, Uttar Pradesh, India. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: Biotechnology Industry Research Assistance Council, DBT-Ramalingaswami, Department of Biotechnology, Ministry of Science and Technology, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recurrent nature of coronavirus outbreaks, severity of the COVID‐19 pandemic, rapid emergence of novel variants, and concerns over the effectiveness of existing vaccines against novel variants have highlighted the need to develop therapeutic interventions. Targeted efforts to identify inhibitors of crucial viral proteins are the preferred strategy. In this study, we screened FDA‐approved and natural product libraries using in silico approach for potential hits against the SARS‐CoV‐2 main protease (Mpro) and experimentally validated their potency using in vitro biochemical and cell‐based assays. Seven potential hits were identified through in silico screening and were subsequently evaluated in SARS‐CoV‐2‐based cell‐free assays, followed by testing in the HCoV‐229E‐based culture system. Of the tested compounds, 4‐(3,4‐dihydroxyphenyl)‐6,7‐dihydroxy‐1‐isopropyl‐1H‐benzofuro[3,2‐b]pyrazolo[4,3‐e]pyridin‐3(2H)‐one (PubChem CID:71755304, hereafter referred to as STL522228) exhibited significant antiviral activity. Subsequently, its potential as a novel COVID therapeutic molecule was validated in the SARS‐CoV‐2‐culture system, where STL522228 demonstrated superior antiviral activity (EC 50 = 0.44 μ m ) compared to Remdesivir (EC 50 = 0.62 μ m ). Based on these findings, we report the strong anti‐coronavirus activity of STL522228, and propose that it as a promising pan‐ coronavirus Mpro inhibitor for further experimental and preclinical validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansSARS-CoV-2PandemicsAntiviral AgentsProtease InhibitorsMolecular Docking SimulationCoronavirus 3C Proteases

Stichwörter der Autor:innen

in silicoHCoV-229EMproSARS-CoV-2STL522228coronavirus

Substanzen

Antiviral AgentsProtease Inhibitors3C-like proteinase, SARS-CoV-2Coronavirus 3C Proteases

Autor:innen und Institutionen

  • Department of Life Sciences, School of Natural Sciences, Shiv Nadar Institution of Eminence, Greater Noida, Uttar Pradesh, India.
  • Department of Chemistry, School of Natural Sciences, Shiv Nadar Institution of Eminence, Greater Noida, Uttar Pradesh, India.
  • Department of Biophysics, All India Institute of Medical Sciences, New Delhi, India.
  • Laboratory of Virology, Regional Centre for Biotechnology, NCR Biotech Science Cluster, Faridabad, India.
  • Research and Development Division, Srikara Biologicals Private Limited, Tirupati, India.

ORCID-Profile: Aditya Trivedi, Vandana Kardam, Aekagra Singh, Mohan Babu Appaiahgari, Deepak Sehgal

Förderung

  • Biotechnology Industry Research Assistance Council
  • DBT-Ramalingaswami
  • Department of Biotechnology, Ministry of Science and Technology, India
  • Indian Council of Medical Research
  • Science and Engineering Research Board
  • Department of Biotechnology, Government of West Bengal

Zitieren

APA

Trivedi, A., Kardam, V., Inampudi, K. K., Vrati, S., Gupta, D., Singh, A., Kayampeta, S. R., Appaiahgari, M. B., & Sehgal, D. (2023). Identification of a novel inhibitor of SARS‐CoV ‐2 main protease: an in silico , biochemical, and cell‐based approach. The FEBS Journal. https://doi.org/10.1111/febs.16947

Vancouver

Trivedi A, Kardam V, Inampudi KK, Vrati S, Gupta D, Singh A, et al. Identification of a novel inhibitor of SARS‐CoV ‐2 main protease: an in silico , biochemical, and cell‐based approach. The FEBS Journal. 2023. doi:10.1111/febs.16947

BibTeX
@article{Trivedi2023,
  author = {Trivedi, Aditya and Kardam, Vandana and Inampudi, Krishna Kishore and Vrati, Sudhanshu and Gupta, Dharmender and Singh, Aekagra and Kayampeta, Sarala Rani and Appaiahgari, Mohan Babu and Sehgal, Deepak},
  title = {Identification of a novel inhibitor of SARS‐CoV ‐2 main protease: an in silico , biochemical, and cell‐based approach},
  journal = {The FEBS Journal},
  year = {2023},
  doi = {10.1111/febs.16947}
}
Kostenlos starten →